US 12,458,627 B2
Autotaxin inhibitors and uses thereof
Gretchen Bain, San Diego, CA (US); Jillian Frances Evans, San Diego, CA (US); John Howard Hutchinson, San Diego, CA (US); and David Lonergan, San Marcos, CA (US)
Assigned to DF 2024 IP Acquisition, LLC, New York, NY (US)
Filed by DF 2024 IP Acquisition, LLC, New York, NY (US)
Filed on Mar. 17, 2020, as Appl. No. 16/821,365.
Application 16/821,365 is a division of application No. 15/574,769, granted, now 10,632,104, previously published as PCT/US2016/033933, filed on May 24, 2016.
Claims priority of provisional application 62/167,216, filed on May 27, 2015.
Prior Publication US 2020/0215034 A1, Jul. 9, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4155 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/4439 (2006.01); A61P 1/16 (2006.01)
CPC A61K 31/4155 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/08 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/4439 (2013.01); A61P 1/16 (2018.01)] 15 Claims
 
1. A method for treating steatosis, in a mammal, the method comprising the oral administration to the mammal of an autotaxin inhibitor that has the following structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, or solvate thereof.